Teva Pharmaceutical Indus... (TEVA)
NYSE: TEVA
· Real-Time Price · USD
18.54
0.18 (1.01%)
At close: Sep 26, 2025, 11:03 AM
1.01% (1D)
| Bid | 18.5 |
| Market Cap | 21.27B |
| Revenue (ttm) | 16.63B |
| Net Income (ttm) | -158M |
| EPS (ttm) | -0.15 |
| PE Ratio (ttm) | -123.6 |
| Forward PE | 7.04 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 18.65 |
| Volume | 2,645,862 |
| Avg. Volume (20D) | 11,068,341 |
| Open | 18.48 |
| Previous Close | 18.36 |
| Day's Range | 18.38 - 18.70 |
| 52-Week Range | 12.47 - 22.80 |
| Beta | 0.72 |
| Ex-Dividend Date | n/a |
About TEVA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol TEVA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for TEVA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsTeva Pharmaceutical Industries Limited is scheduled to release its earnings on
Nov 5, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+1.75%
Shares of several biotechnology stocks are trading...
Unlock content with
Pro Subscription
4 months ago
+4.42%
Teva Pharmaceutical Industries shares are trading higher after the company along with Biolojic Design initiated IND-enabling studies of BD9.
17 hours ago · seekingalpha.com
Teva Pharmaceuticals: Pipeline Momentum Signals New Era For InvestorsWall Street is slowly beginning to understand that Teva Pharmaceutical Industries Limited is rapidly transforming from a generic medication supplier into one of the key players in the CNS treatment ma...
